Finland's Optomed Q4 revenue falls 5.6%

Optomed Oyj

10/02/2026 07:10

Overview

Finland's handheld fundus camera maker's Q4 2025 revenue fell 5.6%

Devices segment revenue declined 6.7% in Q4 2025

Company raised EUR 6 mln through a successful share issue

Outlook

Optomed expects full-year 2026 revenue to grow compared to 2025

Company anticipates continued uncertainty in U.S. market in 2026

Optomed to focus on expanding AI-enabled screening solutions in 2026

Result Drivers

LARGE ORDER IMPACT - Q4 2025 revenue decline attributed to absence of large one-time order from previous year

SOFTWARE COSTS - One-time personnel and license costs in Software segment impacted EBITDA

SHARE ISSUE - Optomed raised EUR 6 mln through share issue to support growth strategy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
EUR 4.81 mln
EUR 5 mln (2 Analysts)
Q4 EPS
-EUR 0.10
Q4 Net Income
-EUR 1.89 mln
Q4 EBITDA
-EUR 1.33 mln
Q4 EBITDA Margin
-27.70%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Optomed Oyj is €4.45, about 12.2% above its February 9 closing price of €3.97

Press Release: ID:nWkr4lKhcb

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)